Diagnostic performance and cost effectiveness of measurements of plasma N-terminal pro brain natriuretic peptide in patients presenting with acute dyspnea or peripheral edema

International Journal of Cardiology

Volumn 135, Issue 2, 2009, Pages 165-174

  Behnes, Michael ^a   Brueckmann, Martina ^a   Ahmad Nejad, Parviz ^a   Lang, Siegfried ^a   Wolpert, Christian ^a   Elmas, Elif ^a   Kaelsch, Thorsten ^a   Gruettner, Joachim ^a   Weiß, Christel ^a   Borggrefe, Martin ^a   Neumaier, Michael ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cost; Dyspnea; Edema; Heart failure; NT proBNP

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ACUTE HEART FAILURE; ADULT; AGED; ANAMNESIS; ARTICLE; CONGESTIVE HEART FAILURE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MONEY; PERFORMANCE; PERIPHERAL EDEMA; PHYSICAL EXAMINATION; PREDICTION; PRIORITY JOURNAL; RESOURCE ALLOCATION; THORAX RADIOGRAPHY;

ACUTE DISEASE; AGED; BIOLOGICAL MARKERS; CHEMISTRY, CLINICAL; COST SAVINGS; COST-BENEFIT ANALYSIS; DYSPNEA; EDEMA; EMERGENCY MEDICAL SERVICES; FEMALE; HEART FAILURE; HOSPITAL COSTS; HUMANS; LOGISTIC MODELS; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 67349102354     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.03.045     Document Type: Article

References (36)

1. Thom T., Haase N., Rosamond W., et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2006) 113:e85-e151
2. Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 1115-1140
3. The Federal Health Monitoring of the Federal Ministry of Health-Federal Republic of Germany. http://www.gbe-bund.de. Search pathway: Expenditures, costs and financing - expenditures for specific diseases - tables - cost of illness by facility and sex - diseases of the circulatory system - other forms of heart disease - heart failure (I50) - Select hospitals.
4. McCullough P.A., Nowak R.M., McCord J., et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 106 (2002) 416-422
5. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347 (2002) 161-167
6. Januzzi Jr. J.L., Camargo C.A., Anwaruddin S., et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95 (2005) 948-954
7. Maisel A., Hollander J.E., Guss D., et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 44 (2004) 1328-1333
8. Morrison L.K., Harrison A., Krishnaswamy P., Kazanegra R., Clopton P., and Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. Am Coll Cardiol 39 (2002) 202-209
9. Nielsen L.S., Svanegaard J., Klitgaard N.A., and Egeblad H. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. Eur J Heart Fail 6 (2004) 63-70
10. Mueller C., Scholer A., Laule-Kilian K., et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 350 (2004) 647-654
11. Mueller C., Laule-Kilian K., Schindler C., et al. Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med 166 (2006) 1081-1087
12. Nielsen O.W., McDonagh T.A., Robb S.D., and Dargie H.J. Retrospective analysis of the cost effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 41 (2003) 113-120
13. Heidenreich P.A., Gubens M.A., Fonarow G.C., Konstam M.A., Stevenson L.W., and Shekelle P.G. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 43 (2004) 1019-1026
14. Siebert U., Januzzi Jr. J.L., Beinfeld M.T., Cameron R., and Gazelle G.S. Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. Am J Cardiol 98 (2006) 800-805
15. Nieminen M.S., Böhm M., Cowie M.R., et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 26 4 (2005) 384-416
16. Di Serio F., Ruggieri V., Varraso L., De Sario R., Mastrorilli A., and Pansini N. Analytical evaluation of the Dade Behring Dimension RxL automated N-Terminal proBNP (NT-proBNP) method and comparison with the Roche Elecsys 2010. Clin Chem Lab Med 43 (2005) 1263-1273
17. Mueller C., Breidthardt T., Laule-Kilian K., Christ M., and Perruchoud A. The integration of BNP and NT-proBNP into clinical medicine. Swiss Med Wkly 137 (2007) 4-12
18. Schwam E. Rapid measurement of B-type natriuretic peptides reduced time to discharge and treatment costs in patients with acute dyspnea. ACP J Club 142 (2005) A14
19. Hohl C.M., Mitelman B.Y., Wyer P., and Lang E. Should emergency phycicians use B-type natriuretic peptide testing in patients with unexplained dyspnea?. Can J Emerg Med 5 (2003) 162-165
20. Lainchbury J.G., Campbell E., Frampton C.M., Yandle T.G., Nicholls M.G., and Richards A.M. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 42 (2003) 728-735
21. Bayés-Genís A., Santaló-Bel M., Zapico-Muñiz E., et al. N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail 6 (2004) 301-308
22. Januzzi J.L., van Kimmenade R., Lainchbury J., et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 27 (2006) 330-337
23. Vasan R.S., Benjamin E.J., Larson M.G., et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 288 (2002) 1252-1259
24. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., Mahoney D.W., Bailey K.R., and Burnett J.C. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation 109 (2004) 3176-3181
25. Anand I.S., Fisher L.D., Chiang Y.T., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107 (2003) 1278-1283
26. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., and Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000) 1126-1130
27. Jourdain P., Jondeau G., Funck F., et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 49 (2007) 1733-1739
28. Wright S.P., Doughty R.N., Pearl A., et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol 42 (2003) 1793-1800
29. Mark D.B., and Felker G.M. B-type natriuretic peptide - a biomarker for all seasons?. N Engl J Med 350 (2004) 718-720
30. Schuenemann H.J., and Akl E. Rapid measurement of B-type natriuretic peptides reduced time to discharge and treatment costs in patients with acute dyspnea. ACP J Club 141 (2004) 35
31. Apple F.S., Murakami M.M., Pearce L.A., and Herzog C.A. Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem 50 (2004) 2279-2285
32. Anwaruddin S., Lloyd-Jones D.M., Baggish A., et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 47 (2006) 91-97
33. Kucher N., Printzen G., and Goldhaber S.Z. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 107 (2003) 2545-2547
34. Kucher N., Printzen G., Doernhoefer T., Windecker S., Meier B., and Hess O.M. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 107 (2003) 1576-1578
35. Brueckmann M., Huhle G., Lang S., et al. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 112 (2005) 527-534
36. Hohl C.M. Should natriuretic peptide testing be incorporated into emergency medicine practice?. Can J Emerg Med 8 (2006) 259-261